Zura Bio
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 15
- Market Cap
- $269.2M
- Introduction
Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.
Zura Bio Launches Phase II TibuSHIELD Trial for Novel Dual-Inhibitor in Hidradenitis Suppurativa
Zura Bio has initiated the Phase II TibuSHIELD trial evaluating tibulizumab, a first-of-its-kind dual inhibitor targeting both BAFF and IL-17A pathways in patients with moderate to severe hidradenitis suppurativa.
Zura Bio Launches Phase 2 TibuSURE Study of Tibulizumab for Systemic Sclerosis
Zura Bio has initiated a global Phase 2 trial, TibuSURE, to evaluate tibulizumab for treating systemic sclerosis (SSc) in adults, marking a significant step in addressing this complex autoimmune disease.